A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

Trial Profile

A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex Oromucosal Spray (Sativex; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Cancer pain
  • Focus Registrational; Therapeutic Use
  • Acronyms SPRAY-III
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2015 Top-line results published in a GW Pharmaceuticals media release.
    • 08 Jan 2015 Primary endpoint has not been met (percent improvement in mean pain score from baseline to end of treatment, evaluated by patients using a 0 to 10 numeric rating scale), according to a GW Pharmaceuticals media release.
    • 17 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top